BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and option deal with ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [CONFLICT] China plans CPU-only exascale supercomputer with 47,000 homemade processors, record 2 Exaflops of performance without GPUs — Lingshen super said to use Huawei Kunpeng servers and no foreign-made components
- [FINANCE] Investors brace for Yum China earnings amid SSS growth concerns
- [CONFLICT] House Democrats urge Trump to keep US ban on Chinese cars in place
- [CONFLICT] Silk Typhoon Extradition: State-Sponsored APT Operator Accountability & Persistence TTPs
- [CONFLICT] China’s calls to open Hormuz show the limits of its ties to Iran, experts say
- [CONFLICT] Hidden Chinese history of Australia’s gold rush is going global